On September 1st, 2023, UnitedHealthcare completed its first phase as part of a two-phase approach to eliminate prior authorization requirements for various procedures and services across their commercial, Medicare, and Medicaid plans

The Centers for Medicare & Medicaid Services (CMS) announced on June 22nd a detailed plan regarding its coverage of new Alzheimer’s treatments, following the full approval of Eisai’s Leqembi by the FDA.

We are pleased to release the next edition of our Windrose Consulting Group: Global News Roundup for Q2 2023.

In 2019, the Swiss Federal Council modified the Therapeutic Products Act (TPA) to facilitate market access, improve drug safety, and increase transparency in Switzerland’s P&MA system.

In this Q&A, we are featuring our Summer Interns, Amy Brinster, Aashray Gupta and Isaac Tolley

Since entering the World Trade Organization, China’s Pharmaceutical industry has experienced rapid growth in value, from $123.7 billion in 2016 to an estimated $573.5 billion in 2022

We are pleased to release the next edition of our Windrose Consulting Group: Global News Roundup for Q1 2023.

We are pleased to release the next edition of our Windrose Consulting Group: Global News Roundup for Q3 2022.

In this Q&A, we are featuring Jude Baroudi and his career journey and highlights to date.

In an article, published on Pharmexec, Anaïs Frappé, Amy Morgan and Crystal Leung, review market access opportunities in China through private payers, and how Commercial Health Insurance (CHI) can bring value before, during, and after NRDL inclusion.

On August 16th, 2022, President Biden signed the Inflation Reduction Act into law, which will bring reforms to Medicare spending and coverage, impacting manufacturers’ long-term P&MA strategy and payer decision-making.

Windrose Consulting Group’s take on The Foreign Data Problem: Implications of the FDA’s New Criteria for Foreign Data Submissions.

We are pleased to release the next edition of our Windrose Consulting Group: Global News Roundup for Q2 2022.

In this Q&A, we are featuring Daisy Pharoah and her career journey and highlights to date.

Last week during the second session of our P&MA strategy course (a collaboration between Windrose and Cambridge University), our guest Andrew Walker produced this nugget:

“Uncertainty has been weaponised by payers”

On Friday, April 22nd, 2022, Biogen announced that it had withdrawn the marketing application in the EU for aducanumab (Aduhelm), its monoclonal antibody that targets aggregated forms of amyloid beta found in the brains of Alzheimer’s patients.

We are pleased to release the second edition of our Windrose Consulting Group: Global News Roundup for Q1 2022.

The application of biomarkers in therapy areas beyond oncology will likely play an ever-crucial role in developing more targeted therapies in high unmet need indications, while providing payers with new attributes by which to assess a new treatment’s value.

This article will describe the cost-containment measures introduced by the new government and how they influence drugs’ pricing and market access potential.

As a third installment of our Aduhelm coverage, we look at the recently announced draft National Coverage Determination (NCD) by the Centers for Medicare and Medicaid Services (CMS).